|
Dec 17
|
Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
|
|
Dec 17
|
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
|
|
Dec 16
|
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
|
|
Dec 16
|
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
|
|
Dec 13
|
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
|
|
Dec 12
|
How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket
|
|
Dec 11
|
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
|
|
Dec 11
|
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
|
|
Dec 11
|
The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International
|
|
Dec 11
|
Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?
|
|
Dec 10
|
Top Analyst Reports for Alphabet, Oracle & Merck
|
|
Oct 1
|
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
|
|
Oct 1
|
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
|
|
Sep 30
|
Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth
|
|
Sep 30
|
Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth
|
|
Sep 29
|
Is Merck Stock a Buy?
|
|
Sep 27
|
Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
|
|
Sep 26
|
Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In?
|
|
Sep 26
|
EVAX Process Continues to Garner Interest and Investment
|
|
Sep 26
|
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
|